港股異動 | 中芯國際升超8%,科創板IPO獲566倍超額認購
uSMART友信智投7月8日消息,週三港股,中芯國際高開高走,截至11:36分,中芯國際升8.48%,報39.65港元。
中芯國際科創板IPO獲566倍超額認購,中芯國際此次上市的發行價格為27.46元/股,募資額達453億元,是自2010年以來A股最大規模的IPO。
中芯國際昨晚公佈科創板網上發行申購情況及中簽率公告,在超額配售選擇權及網上、網下回撥機制啟動後,網上發行最終中簽率為0.21%,為科創板新股中簽第二高。據不完全統計,目前已上市的119家科創板企業的平均中簽率為0.0485%。相比之下,中芯國際的這一中簽率遠高平均值,僅次於中國通號的0.23%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.